Cutler Group’s IGC Pharma IGC Stock Holding History

Cutler Group’s Portfolio IGC Stock Details IGC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-8,900	Closed	-$1K	–	5992
2021 Q2	$1K	Sell	8,900 -1,700	-16%	-$2.6K	﹤0.01%	5307
2021 Q1	$1K	Buy	+10,600	New	+$19.3K	﹤0.01%	5247

Other funds holding IGC

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dearborn Partners Chicago, Illinois $1.85B AUM 6.59% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

VIA

Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Cutler Group's IGC Position: Q3 2022 in Review

Cutler Group sold out of IGC Pharma (IGC) in Q3 2022, closing a stake of 796 shares.

Cutler Group first reported a position in IGC in Q1 2019 and held it in 14 quarters. The position peaked at $18K in Q1 2021. 26 funds tracked by Wall St. Rank hold IGC as of Q3 2022.

Cutler Group reported no remaining IGC Pharma position as of Q3 2022 after selling out during the quarter.
Cutler Group sold 796 IGC Pharma shares in Q3 2022.
Cutler Group first reported a position in IGC Pharma in Q1 2019 and held it in 14 quarters.
Cutler Group's IGC Pharma position peaked at $18K in Q1 2021.
26 funds tracked by Wall St. Rank held IGC Pharma as of Q3 2022.

Based on Cutler Group's 13F filing for Q3 2022, filed 25 Oct 2022.